Isoniazid probably leads to lower tuberculosis compared with no treatment (moderate certainty).
Isoniazid probably leads to higher INH hepatotoxicity Jaundice, elevated bilirubin, elevated liver… compared with no treatment (moderate certainty).
Isoniazid showed no clear difference in all‐cause mortality compared with no treatment (low certainty).
It is very uncertain whether rifampicin plus isoniazid changes active TB compared with isoniazid (very low certainty).
Rifampicin plus isoniazid showed no clear difference in adherence compared with isoniazid (high certainty).
Rifampicin plus isoniazid showed no clear difference in treatment‐limiting adverse events compared with isoniazid (low certainty).
Rifampicin plus isoniazid showed no clear difference in hepatotoxicity compared with isoniazid (low certainty).
Rifapentine plus isoniazid weekly showed no clear difference in active TB compared with isoniazid daily (moderate certainty).
Rifapentine plus isoniazid weekly probably leads to higher adherence compared with isoniazid daily (moderate certainty).
Rifapentine plus isoniazid weekly probably leads to higher treatment‐limiting adverse events compared with isoniazid daily (moderate certainty).
Rifapentine plus isoniazid weekly leads to lower hepatotoxicity compared with isoniazid daily (high certainty).
Isoniazid prophylaxis may leads to lower active TB compared with placebo (low certainty).
Isoniazid prophylaxis may leads to lower death compared with placebo (low certainty).
It is very uncertain whether isoniazid prophylaxis changes active TB compared with placebo (very low certainty).
It is very uncertain whether isoniazid prophylaxis changes death compared with placebo (very low certainty).
It is very uncertain whether oral Isoniazid (INH) changes clinical failure clinical observation compared with no intervention (very low certainty).
It is very uncertain whether oral isoniazid plus rifampicin changes clinical failure clinical observation compared with no intervention (very low certainty).